<DOC>
	<DOCNO>NCT02322632</DOCNO>
	<brief_summary>An open-label , balance , randomize , two-treatment , two-sequence , two-period , single-dose , crossover oral bioequivalence study healthy subject fast condition .</brief_summary>
	<brief_title>Bioequivalence Study Paricalcitol Capsules , 4 mcg Under Fasting Conditions</brief_title>
	<detailed_description>An open-label , balance , randomize , two-treatment , two-sequence , two-period , single-dose , crossover oral bioequivalence study Paricalcitol Capsules 4 mcg Dr. Reddy 's Laboratories Limited Zemplar® Capsules 4 mcg Abbott Laboratories , USA healthy , adult , human subject fast condition .</detailed_description>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>Healthy , adult , human volunteer 18 55 year age ( inclusive ) live around Ahmedabad city western part India . Having Body Mass Index ( BMI ) 18.5 24.9 ( inclusive ) , calculate weight kg/height m2 . Have significant disease clinically significant abnormal finding screen , medical history , clinical examination , laboratory evaluation , 12 lead ECG Xray chest ( posteroanterior view ) recording . Volunteers normal calcium , phosphorous status hypertensive status order avoid effect vitamin D concentration blood . Able comply study procedure , opinion Principal investigator . Able give voluntary inform consent participation trial . In case female subjects* : Surgically sterilize least 6 month prior study participation ; Or If child bear potential willing use suitable effective double barrier contraceptive method intra uterine device study . Urine pregnancy test ( female subjects* ) must negative time screen . *No female subject enrol study . Known hypersensitivity idiosyncratic reaction Paricalcitol excipients drug substance . History presence disease condition might compromise haemopoietic , renal , hepatic , endocrine , pulmonary , central nervous , cardiovascular , immunological , dermatological , gastrointestinal body system . Ingestion Use medication time 14 day prior dose . In case subject selection discretion Principal Investigator . Any history presence asthma ( include aspirin induce asthma ) nasal polyp NSAID induce urticaria . Consumption Grapefruits product within period 48 hour prior checkin . A recent history harmful use alcohol ( less 2 year ) , i.e . alcohol consumption 14 standard drink per week men 7 standard drink per week woman ( A standard drink define 360 ml beer 150 ml wine 45 ml 40 % distilled spirit , rum , whisky , brandy etc ) . `` consumption alcohol alcoholic product within 48 hous prior checkin . Smokers , smoke 10 10 cigarette / day inability abstain smoking study . The presence clinically significant abnormal laboratory value screen . Use recreational drug history drug addiction test positive prestudy drug scan . History presence psychiatric disorder . A history difficulty donate blood . Donation blood ( 1 unit 350 mL ) receipt investigational medicinal product participation drug research study within period 90 day prior first dose study medication . Elimination halflife study drug take consideration inclusion subject study . Note : In case blood loss ≤ 200 mL , subject may enrol 60 day blood donation last sample previous study . A positive hepatitis screen include hepatitis B surface antigen anti HCV antibody . A positive test result antiHIV antibody . An unusual diet , whatever reason ( e.g . lowsodium ) , four week prior receive study drug throughout subject ' participation study . In case subject selection discretion Principal Investigator . Nursing mother ( female ) * . *No female subject enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>